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44 The Journal of Thoracic and Cardioackground: Increasing data implicate histologic grade and radiographic appear-
nce along with tumor size as key prognostic indicators for pulmonary adenocar-
inoma. The impact of tumor location on prognosis has not been examined.
ethods: The records of 530 consecutive patients with pulmonary adenocarcinoma
athologically staged between June 1979 and July 2002 were reviewed. All patients
ad a preoperative computed tomographic scan of the chest and underwent surgical
taging by mediastinoscopy, lymph node sampling, or lymph node dissection.
atients with bronchioalveolar cell carcinoma were excluded. Peripheral tumors
ere compared with central tumors with regard to stage and survival. A tumor was
onsidered to be central if visualized within the inner third of the lung field or seen
ronchoscopically. Patients with T1 cancers were further analyzed on the basis of
umor size. Survival was determined by the Kaplan-Meier analysis and comparisons
ere made by the log-rank method.
esults: Central tumors were more advanced and demonstrated a significantly (P 
0001) poorer survival than peripheral tumors (median 18 vs 39 months). Sixty
ercent of patients with central tumors had stage III or stage IV disease compared
ith 25% of those with peripheral tumors. Central T1 tumors, however, demon-
trated a 50% incidence of lymph node involvement. Although the incidence of
ymph node metastases increased incrementally with the size of peripheral T1
umors, it remained 50% for central T1 tumors irrespective of size.
onclusion: Tumor location for pulmonary adenocarcinoma should be considered
hen planning therapy. Central tumors have a high incidence of lymph node
etastases (regardless of size) and a poorer prognosis.
umor staging is important in determining the optimal pathway for the
treatment of operable non–small cell lung cancer (NSCLC). For patients with
stage I NSCLC, lobectomy is the gold standard of therapy on the basis of the
esults of the Lung Cancer Study Group’s landmark study, which compared lobec-
omy and sublobar resection.1 Lesser resection has been associated with increased
ocal failure and is used in most centers for the high-risk patient.2 Recently there has
een increased interest in limited resection,2-4 with the realization that certain
rognostic factors separate from the TNM staging scheme may better predict
avorable lesions that can be appropriately treated with less than lobectomy
esection.
The current TNM system does not address issues such as histologic features,
mall tumor size, and radiographic appearance. All of these factors have been the
ubject of recent discussion. For instance, tumors that have a predominately ground-
lass appearance on computed tomographic scan are more likely to have favorable
linical behavior.5 Adenocarcinomas and squamous cancers appear to have a dif-
erent propensity for lymph node metastasis. In one series comparing the behavior
vascular Surgery ● September 2006
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TSf adenocarcinoma and squamous cancers, the authors con-
luded that although limited resection was feasible for squa-
ous cancers 2 cm or less, these operations should not be
erformed in adenocarcinomas over 1 cm because of an
ncreased incidence of lymph node metastasis.6
The poor correlation between clinical and pathologic
taging in stage I NSCLC that has been demonstrated in
everal studies makes it difficult to select an appropriate
peration, particularly in the compromised patient. Several
tudies have reported that the propensity for lymph node
nvolvement varies significantly by the lobar location and
ide of the tumor.7,8 Other studies have demonstrated the
dverse effect of moderate-to-poor differentiation.9 Central
r peripheral location of tumor, which can be determined by
omputed tomography, however, has not been examined as
possible factor affecting survival independent of stage. In
arlier reports, we10 noted a significantly higher liklihood of
alse negative staging of mediastinal lymph nodes for cen-
ral versus peripheral tumors, particularly for adenocarci-
oma. We also showed a 2-fold difference (20% vs 45%) in
urvival after resection and adjuvant chemo-radiotherapy be-
ween these patients, although the difference was not signifi-
ant. Although lung cancers usually present with more ad-
anced disease, important differences in survival may exist
etween central and peripheral tumors independent of stage
hat may be helpful in selecting therapy, particularly for
ompromised patients or patients with clinical stage I
isease.
ethods
he records of 530 consecutive patients with pulmonary adeno-
arcinoma out of 1275 patients with lung cancer pathologically
taged between June 1979 and July 2002 were reviewed in our
ung cancer database. The T and N status of all patients was
pdated to conform to the current international system for staging
ung cancer. Survival data were available for all patients. All
atients had a preoperative computed tomographic scan of the
hest and all patients underwent surgical staging by mediastinos-
opy, lymph node sampling, or lymph node dissection. The central
nd peripheral location of each tumor had been recorded prospec-
ively by a single thoracic surgeon (B.D.). Patients with bron-
hioalveolar cell carcinoma were not included. Eleven patients had
synchronous tumor of other histologic type, either in the same
obe or a different lobe, and were excluded from further analysis.
umor location could not be verified in 5 additional patients and
hese were excluded. A total of 514 patients were available for
eview. A tumor was considered to be central if it was visualized
ithin the inner third of the lung field or seen bronchoscopically.
tage at presentation between peripheral and central tumors was
Abbreviations and Acronyms
NSCLC non–small cell lung cancerompared by the Fisher exact test. Survival was determined by the s
The Journal of Thoracicaplan-Meier analysis for overall and stage-based comparisons
sing the log-rank method. Survival for patients with stage I
umors was further analyzed according to age, sex, tumor size, and
he presence/absence of pleural involvement. Factors demonstrat-
ng a significant survival difference at .10 were then compared by
multivariable Cox regression forward analysis. Statistics were
erformed with SSPS statistical software version 10.1 (SPSS Inc,
hicago, Ill). The nodal status of 291 patients with clinical T1
ancers (tumors 3 cm in size or less) was further analyzed on the
asis of size.
esults
total of 403 patients had peripheral tumors and 111
atients had central tumors. Central tumors were more ad-
anced. Sixty percent (67/111) of these patients presented
ith stage III or stage IV disease and 75% (304/403) of
atients with peripheral tumors presented with stage I or
tage II disease (Table 1). Fifty patients with central tumors
nderwent a lobectomy, 20 patients a pneumonectomy, 1
atient a segmentectomy, and 1 patient a wedge resection.
ix patients had unresectable tumors at operation and 33
atients did not come to surgery. Conversely, 305 patients
ith peripheral tumors underwent a lobectomy, only 4 un-
erwent a pneumonectomy, 11 a segmentectomy, and 51 a
edge resection. All except 8 patients undergoing wedge
esection had lymph node evaluation. Ten had unresectable
umors at operation and only 4 did not come to surgery.
ixty-six patients with central tumors received radiation. In
3 it was in the neoadjuvant setting and in 35 in the adjuvant
etting. Twenty-seven patients with peripheral tumors re-
eived neoadjuvant radiation and 87 received adjuvant radio-
herapy. Twenty-five patients with central tumors received
eoadjuvant chemotherapy and 15 received postoperative ad-
uvant chemotherapy. A total of 156 patients with peripheral
umors received chemotherapy. In 20 patients it was given in
he neoadjuvant setting and in 31 it was given as adjuvant
reatment. These factors were not considered in the analysis
f survival.
Survival was significantly poorer (P  .0001) in patients
ith central tumors than in those with peripheral tumors
median 18 months vs 39 months, Figure 1). When adjusted
or stage, however, only stage I tumors demonstrated a
ABLE 1. Frequencies of central and peripheral tumors
tratified by stage
tage Central (n  111) Peripheral (n  403)
I 26 (23%) 243 (60%)*
II 18 (16%) 61 (15%)
III 49 (44%) 72 (18%)
IV 18 (16%) 27 (7%)
 .001 for comparison of stage I versus higher stage in central versus
eripheral groups (the Fisher exact test).ignificant survival difference based on location (P 
and Cardiovascular Surgery ● Volume 132, Number 3 545
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TS0299). Patients with peripheral stage I tumors had a better
verall median survival than did those with central tumors
60 months vs 41 months, Figure 2). Univariate analysis dem-
nstrated significance for age, sex, and location. Mutivariable
nalysis similarly demonstrated significance for age and sex
ith location approaching significance (Table 2). The nodal
tatus of the subset of patients with clinical T1 tumors is
emonstrated in Tables 3 and 4. Fifty percent of patients
ith central T1 tumors had nodal disease. Peripheral tu-
ors, on the other hand, had a 24% incidence of nodal
etastasis (Table 5). Seventeen percent of patients with
eripheral tumors 2 cm in size or less had nodal disease.
iscussion
ew pulmonary screening programs using computed to-
ography are identifying increasing numbers of small46 The Journal of Thoracic and Cardiovascular Surgery ● Septearly-stage lung cancers.11 These clinical T1 N0 lesions
ave been targeted as potential candidates for limited
esection surgery. The benefits of limited resection sur-
ery include improved residual pulmonary function12 and
ecreased operative mortality. Attempts at limited resec-
ion surgery in the past as standard therapy, however,
ave resulted in increased local failure, leaving lobec-
omy as the current standard for the treatment of lung
ancer. The identification of improved prognostic factors
n detecting favorable early lesions has sparked renewed
nterest in limited resection surgery. These new factors
utside the standard TNM staging scheme include strat-
fication of size within the T1 classification, histologic
eatures, and radiographic appearance. Tumor location,
owever, has not been examined as a potential prognostic
actor for small T1 N0 lesions.
Figure 1. Graph demonstrating Kaplan-Meier
survival stratified by adenocarcinoma location
for the overall cohort. There is a significant dif-
ference between peripheral and central loca-
tions (P < .0001). CP, Central/peripheral.
Figure 2. Graph demonstrating Kaplan-Meier
survival for stage I adenocarcinomas stratified
by central and peripheral locations. There is a
significant survival difference between the two
locations (P  .03). CP, Central/peripheral.mber 2006
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TSTumor size affects survival.13,14 Even within the current
NM staging scheme, those lesions classified as T1 may be
urther stratified to reflect prognosis. The association of
ncreasing size with nodal involvement may in part explain
his. Even with adenocarcinomas 1 cm in size or less,
hta,15 Wu,16 and their colleagues reported a small inci-
ence of micrometastasis, and Ichinose with his group17
emonstrated lymphatic vessel invasion in 25% of patients
ith tumors 1 cm or less. Occult nodal involvement within
umors less than 1 cm, previously undetected by standard
taining schemes, is now being identified increasingly with
he use of immunohistochemical evaluation. Although it is
ow evident that adenocarcinoma of any size may harbor
ccult nodal disease, increased lymphatic spread and hematog-
nous metastases are demonstrated at higher incidence for
umors greater than 2 cm. Finally, Wisnivesky, Yankelevitz,
nd Henschke18 identified improved curability with decreas-
ng tumor size for T1 N0 lesions. In our series, the incidence
f lymph node metastases and tumor stage increased with
umor size for peripheral tumors (Table 4). However, the
ncidence of nodal disease was 50% for central T1 tumors of
ny size. Both central and peripheral tumors, regardless of
ize, may harbor occult nodal disease. It is clear from our
ata that central tumors are rarely, if ever, suitable for
ublobar resection and that even with peripheral adenocar-
inomas, sublobar resection should only be considered after
horough evaluation of the lobar, hilar, and mediastinal
ymph nodes. In our series, 17% of peripheral tumors 2 cm
n size or less had nodal metastases at the time of resection.
It would be expected that small early-stage lesions de-
oid of lymphatic invasion, regardless of location, treated
y adequate surgical resection should demonstrate similar
urvival. In our experience when comparing pathologically
taged T1 N0 adenocarcinomas of peripheral and central
ABLE 2. Cox regression multivariable for variables in-
uencing survival in stage I pulmonary adenocarcinoma
Significance
Age .013
Sex .001
Central/peripheral .070
Visceral pleural involvement .569
ariables include sex, age, visceral pleural involvement, and location.
tatistical significance is achieved by a value less than .05.
ABLE 3. N staging of central T1 tumors
umor size (cm) N1 N2 N3
0-1.0 1 1 0
1.1-2.0 0 5 0
2.1-3.0 4 3 0epresents the N stage for patients with T1 central tumors by size. w
The Journal of Thoracicocation, there was a statistically significant difference in
urvival by univariate analysis. However, in a multivariable
nalysis this significance was diminished (P  .07) and the
ifference could be explained by either sex or age alone
Table 2). The isolated significance for stage I lesions may
ossibly reflect a higher incidence of occult nodal involve-
ent for centrally located tumors. Almost 50% of all central
umors 3 cm or less demonstrated nodal involvement,
hereas comparatively fewer peripheral lesions were lymph
ode positive. Peripheral lesions also demonstrated decreas-
ng nodal involvement when stratified by size within the T1
lassification. An argument can therefore be made that
entral tumors should warrant more aggressive therapy.
oldstein and colleagues19 identified characteristics such as
ncreasing nuclear grade and central fibrosis as markers of
ncreased lymphatic invasion, suggesting the addition of
djuvant therapy when identified within smaller lesions.
Overall, central adenocarcinomas present at a later stage.
ocation does not appear to play a role in prognosis when
omparing stage-adjusted advanced lesions. There is, how-
ver, a difference in survival between stage I tumors of
entral and peripheral location. This difference may be
ttributed to a higher incidence of lymph node involvement
or T1 central tumors. This may also explain the overall
endency of central lesions to be more advanced (stages III
nd IV) at presentation. This difference should be taken into
onsideration when defining treatment. Early-stage central
umors should be treated aggressively by lobectomy with
onsideration for adjuvant therapy.
ABLE 4. N staging of peripheral T1 tumors
umor size (cm) N1 N2 N3
0-1.0 19 2 2
1.1-2.0 8 15 1
2.1-3.0 15 20 1
epresents the N stage for patients with T1 peripheral tumors by size.
ABLE 5. Percentage of patients with N1 and N2 positive
esions stratified by tumor size
Tumor location
umor size (cm) Central Peripheral
0-1.0 50% (1/2) 16% (4/25)
1.1-2.0 50% (7/14) 18% (24/137)
2.1-3.0 50% (4/8) 34% (36/105)
epresents the number of patients with T1 disease for both peripheral and
entral tumor location. T1 lesions with N1 or N2 disease are also indicated.
lmost half of all central T1 lesions demonstrate advanced disease. The
ercentage is lower for peripheral tumors and is further stratified by size
ithin the T1 classification.
and Cardiovascular Surgery ● Volume 132, Number 3 547
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